← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Lineage Cell Therapeutics LCTX $245M	62	+4	+7%	$66.3M
27	27 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	57	+22	+63%	$55.8M
28	28 Veracyte VCYT $3.63B	50	+8	+19%	$150M
29	29 Fortress Biotech FBIO $64.7M	48	-9	-16%	$15.9M
30	ATHX 30 DELISTED Athersys, Inc. Common Stock ATHX	46	-11	-19%	$21.2M
31	31 Arbutus Biopharma ABUS $850M	39	-11	-22%	$97.6M
32	32 DELISTED Carisma Therapeutics CARM	39	+7	+22%	$153M
33	AGTC 33 DELISTED Applied Genetic Technologies Corporation AGTC	38	+37	+3,700%	$74.3M
34	34 Imunon IMNN $5.84M	36	+6	+20%	$10.3M
35	35 Opus Genetics IRD $331M	35	0	0%	$6.57M
36	36 Pluri PLUR $12.1M	28	+6	+27%	$3.25M
37	37 uniQure QURE $1.5B	27	+1	+4%	$46.5M
38	38 Vericel Corp VCEL $2.12B	26	+6	+30%	$2.99M
39	39 Fate Therapeutics FATE $231M	22	+1	+5%	$62.4M
40	40 Neurogene NGNE $479M	19	-4	-17%	$41.1M
41	PTE 41 DELISTED PolarityTE, Inc. Common Stock PTE	16	+16	–	$754K
42	42 DELISTED BioLife Solutions BLFS	14	+14	–	$1.32M
43	43 Eterna Therapeutics ERNA $2.39M	7	+2	+40%	$9.86M
44	44 DELISTED Scorpius Holdings, Inc. SCPX	1	0	0%	$4.91M
45	45 Abeona Therapeutics ABEO $270M	–	–	–	–
46	46 Adicet Bio ACET $47.6M	–	–	–	–
47	ACHL 47 DELISTED Achilles Therapeutics ACHL	–	–	–	–
48	48 DELISTED Arcellx ACLX	–	–	–	–
49	ADAP 49 DELISTED Adaptimmune Therapeutics ADAP	–	–	–	–
50	50 Adaptive Biotechnologies ADPT $4.06B	–	–	–	–